For instance, EGCG’s poor oral bioavailability and rapid metabolism result in subtherapeutic plasma and tumor concentrations, which are insufficient for sustained FAS inhibition, required to resensitize resistant tumor cells. This evidence concerns the gene FAS and neoplasm.